Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency-Reference-Cited by-同舟云学术

Eculizumab Is Safe and Effective as a Long-term Treatment for Protein-losing Enteropathy Due to CD55 Deficiency

Published:2019-03 Issue:3 Volume:68 Page:325-333
ISSN:0277-2116
Container-title:Journal of Pediatric Gastroenterology & Nutrition
language:en
Short-container-title:

Author:

Kurolap Alina,Eshach Adiv Orly,Hershkovitz Tova,Tabib Adi,Karbian Netanel,Paperna Tamar,Mory Adi,Vachyan Arcadi,Slijper Nadav,Steinberg Ran,Zohar Yaniv,Mevorach Dror,Baris Feldman Hagit

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Pediatrics, Perinatology, and Child Health

Reference23 articles.

1. Protein-losing enteropathy: case illustrations and clinical review;Umar;Am J Gastroenterol,2010

2. Gastrointestinal lymphatics in health and disease;Alexander;Pathophysiology,2010

3. Loss of CD55 in eculizumab-responsive protein-losing enteropathy;Kurolap;N Engl J Med,2017

4. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis;Ozen;N Engl J Med,2017

5. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies;Lin;Immunology,2001

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Congenital Diarrhoeas and Enteropathies;Nutrients;2024-09-03

2. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments;Orphanet Journal of Rare Diseases;2024-08-08

3. Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation;Pediatric Nephrology;2024-08-03

4. Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation and recovery from chronic kidney failure by eculizumab treatment;2024-03-12

5. Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study;The Lancet;2024-02